Analyst Julian Harrison of BTIG maintained a Buy rating on Apogee Therapeutics, retaining the price target of $137.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Julian Harrison has given his Buy rating due to a combination of factors, primarily centered on the strong clinical performance and differentiation of zumilokibart in atopic dermatitis. He highlights that the drug has shown durable, high-level responses over 52 weeks, meaningful improvements across disease severities and body regions, and a safety and tolerability profile that aligns well with existing therapies, while also offering the prospect of reduced dosing frequency that key opinion leaders believe is commercially attractive.
Harrison also points to upcoming APEX Part B induction data in 2Q26, where higher drug exposure could further raise the efficacy bar for the IL-13/4R class and reinforce the best-in-class narrative. Combined with his valuation work, which incorporates these clinical results and future catalysts into a net present value framework, he concludes that the current share price does not fully reflect zumilokibart’s market potential in atopic dermatitis and additional indications, supporting a favorable risk‑reward and a Buy recommendation on APGE shares.
According to TipRanks, Harrison is a top 100 analyst with an average return of 37.6% and a 54.69% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Apogee Therapeutics, Spyre Therapeutics, and MoonLake Immunotherapeutics.
In another report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $110.00 price target.